Organisation paid for research Program year 2025 Source: CMS Open Payments

MCRC Metroplex Clinical Research Center

Neither a doctor nor a teaching hospital

Research payments

$1,207,886

331 payments

Through program year 2025, MCRC Metroplex Clinical Research Center is reported as receiving $1,207,886 in research payments, across 331 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,567	2
2024	Research	$114	1
2023	Research	$72,382	8
2022	Research	$85,584	8
2021	Research	$265,759	91
2020	Research	$233,540	94
2019	Research	$548,940	127

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $563,299 232 payments
Ucb SA $364,151 57 payments
EMD Serono, Inc. $140,225 13 payments
Sanofi US Services Inc. $86,898 16 payments
AstraZeneca UK Limited $49,266 9 payments
Novartis Pharmaceuticals Corporation $2,350 3 payments
Swedish Orphan Biovitrum AB $1,696 1 payment

Studies the money was for Research payments · program years 2019–2025

M13-549 $120,346 39 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis $102,538 14 payments
M13-542 $99,889 43 payments
Ms200527-0018 $82,471 6 payments
M15-554 $65,364 26 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $62,575 10 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis $61,751 12 payments
M16-063 $60,996 14 payments
Ms 200527-0018 $57,754 7 payments
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica $53,003 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.